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The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor
(EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC). Stage IIIB/IV NSCLC, chemotherapy-
naive patients or patients with recurrences after up to two prior chemotherapy regimens were eligible. Direct sequencing using DNA
from tumour specimens was performed by a central laboratory to detect EGFR mutations. Patients harbouring EGFR mutations
received gefitinib. The primary study objective was response; the secondary objectives were toxicity, overall survival (OS),
progression-free survival (PFS), 1-year survival (1Y-S) and the disease control rate (DCR). Between March 2005 and January 2006, 118
patients were recruited from 15 institutions and were screened for EGFR mutations, which were detected in 32 patients – 28 of whom
were enrolled in the present study. The overall response rate was 75%, the DCR was 96% and the median PFS was 11.5 months. The
median OS has not yet been reached, and the 1Y-S was 79%. Thus, gefitinib chemotherapy in patients with advanced NSCLC
harbouring EGFR mutations was highly effective. This trial documents the feasibility of performing a multicentre phase II study using a
central typing laboratory, demonstrating the benefit to patients of selecting gefitinib treatment based on their EGFR mutation status.
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Gefitinib, a tyrosine kinase inhibitor (TKI), is an orally active
small molecule that functions as a selective epidermal
growth factor receptor (EGFR) inhibitor (Ranson et al, 2002).
Two phase II trials (Fukuoka et al, 2003; Kris et al, 2003) for
previously treated non-small cell lung cancer (NSCLC) (IDEAL-1
and -2, respectively) have documented favourable objective
responses in 14–18% of patients. However, in a phase III
trial (Thatcher et al, 2005), no survival benefit of gefitinib
was observed when compared with best-supportive care (BSC)
for previously treated NSCLC. In contrast, we have seen a
significant survival benefit of erlotinib compared with BSC
as a salvage therapy (BR21); erlotinib is also an EGFR-TKI
and its chemical structure, which is based on quinazoline, is
quite similar to that of gefitinib (Shepherd et al, 2005). Although
we do not know whether differences between gefitinib
and erlotinib were responsible for these different outcomes,
appropriate patient selection to identify good responders is
likely crucial for revealing the clinical benefits of the EGFR-TKI
family.
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retrospective trials (Kaneda et al, 2004; Miller et al, 2004) clearly
show the existence of populations that are more likely to respond
to gefitinib and erlotinib, including women, patients with
adenocarcinoma (especially with bronchial alveolar carcinoma
(BAC)), nonsmokers and Asian patients (compared with Cauca-
sians). Somatic mutations in specific regions of exons 18, 19 and 21
of the ATP-binding domain of EGFR have recently been shown to
have strong associations with sensitivity to gefitinib or erlotinib
(Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004). Consistent
with these findings, the frequencies of these EGFR mutations were
higher in women, patients with adenocarcinoma, nonsmokers and
Asians, all of whom are among the more frequent responders, as
mentioned above (Shigematsu et al, 2005). There are two
characteristic types of EGFR mutations. One is the presence of
in-frame deletions, including the amino acids at codons 746–750
in exon 19, and the other is an amino-acid substitution at codon
858 (L858R) in exon 21. Recent analyses (Bell et al, 2005) of phase
II and III trials for EGFR-TKI, in which patients were not selected
based on their mutation status, have suggested that EGFR
mutations are correlated with response to therapy but are not
correlated with overall survival (OS). Furthermore, EGFR gene
amplification/copy number (Cappuzzo et al, 2005; Hirsch et al,
2005) or overexpression (Hirsch et al, 2003) has been shown to be
a more useful prognostic marker of response to gefitinib
treatment. Patient selection according to EGFR mutation status
may yield a superior survival rate by excluding patients who are
unlikely to respond to gefitinib treatment. However, other
populations that might obtain a clinical benefit from gefitinib
treatment, even in the absence of EGFR mutation, may exist.
Three Japanese groups (Asahina et al, 2006; Inoue et al, 2006;
Yoshida et al, 2007) have reported prospective phase II studies of
gefitinib for advanced-stage NSCLC that were designed to consider
the EGFR mutation status of the patients. All of these studies have
reported a high response rate and extended progression-free
survival (PFS) period, compared with historical controls. However,
all of these studies had a relatively short observation period,
making the data preliminary. Moreover, the original sample size
was calculated after patient selection, and a critical consideration
of the suitability of the assay used to detect the mutations (which
was performed using small paraffin-embedded specimens obtained
from bronchoscopic biopsies), and the estimated EGFR-positive
rate were lacking. Additionally, all the trials were conducted at
single institutions located in one small area of Japan. Thus, the
published data may not be representative of the situation found in
general clinical practice throughout Japan and therefore may not
directly translate to the general feasibility of gefitinib treatment in
Japan.
In view of this situation, we performed a multicentre prospective
phase II trial of gefitinib for advanced NSCLC harbouring EGFR
mutations. We prospectively registered patients from 15 different
institutes in Japan at the beginning of EGFR mutation screening
using a central database. Whether or not tissue was available from
a bronchoscopic biopsy or surgery was not an inclusion criterion.
All the clinical samples from the registered patients were delivered
to a central laboratory that then determined the EGFR mutation
status or the histological BAC features. The analysis of the survival
data was based on a minimum observation period of at least 15
months from the time of entry of the last patient.
MATERIALS AND METHODS
Eligibility criteria
Eligible patients had histologically confirmed stage III NSCLC for
which thoracic irradiation was not indicated or were stage IV.
Chemotherapy-naive patients or those who had previously
received up to two prior chemotherapy regimens, including
those performed in an adjuvant setting, were eligible. Other
eligibility criteria included an age X20 years, measurable
disease, the availability of sufficient amounts of tumour specimen
for EGFR mutation analysis, an Eastern Cooperative Oncology
Group performance status of 0–2, adequate organ
function (WBCp3000ml
 1, plateletsX75000ml
 1, AST and
ALTp100IUl
 1, serum creatinineptwice the upper limit of the
reference range; PaO2X60mmHg). The exclusion criteria included
pulmonary fibrosis, the presence of symptomatic brain metastasis,
active concomitant malignancy, severe heart disease, active
gastrointestinal bleeding and continuous diarrhoea. All the
patients signed a written informed consent form. Approval of this
study and the gene analyses were obtained from the Institutional
Review Board and the Ethics Committee of each hospital.
EGFR gene analysis
Tumour specimens were obtained using bronchial fiberscope or
surgical procedures. The specimens were fixed with formalin and
embedded in paraffin. Four slices (4–5mm) from the embedded
block were sent to a central laboratory (Mitsubishi Chemical Safety
Institute Ltd., Ibaraki, Japan) for genetic analysis. Most of the
tumour specimens were available prior to the registration of this
study. Genomic DNA was isolated from specimens using QIAamp
Micro kits (QIAGEN KK, Tokyo, Japan). The EGFR mutations in
exons 18, 19 and 21, as previously reported (Lynch et al, 2004; Paez
et al, 2004), were determined using polymerase chain reaction
(PCR) amplification and intron–exon boundary primers accord-
ing to the published method. An EGFR registrant mutation in exon
20, which was reported by Pao et al (2005) was also examined
using PCR and the previously reported primers. Polymerase chain
reaction was performed using a Gene Amp PCR System 9700
(Applied Biosystems, Foster City, CA, USA), and the PCR products
were confirmed using a Bioanalyzer 2100 (Agilent Technologies
Inc., Santa Clara, CA, USA), then sequenced directly using the Big
Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems)
and ABI PRISM 3100 (Applied Biosystems). All sequencing
reactions were performed in both forward and reverse directions
and were analysed using the Basic Local Alignment Search Tool
(BLAST); all the electropherograms were reanalysed by visual
inspection to check for mutations. The presence of an EGFR
mutation was confirmed using at least three independent PCR.
All sequence data were sent from the central laboratory to Kinki
University. A principle investigator then confirmed whether or not
the EGFR mutation status was positive, and the results were sent to
the West Japan Thoracic Oncology Group (WJTOG) data centre.
The data centre then informed each participating centre of the
results of the genetic analysis and requested that the eligibility
criteria of the patients be rechecked to insure that only EGFR-
positive subjects were registered in the trial. Each tumour was
categorised according to histology by a pulmonary pathologist
(JF). The percentage of area exhibiting a BAC pattern was also
examined to determine the WHO pathological category.
Treatment plan
Gefitinib (250mgday
 1) was administered once daily. Treatment
was continued uninterrupted until disease progression or intoler-
able toxicity (grade 4 nonhaematological toxicities, any incidents
of interstitial pneumonia or a treatment delay of more than 2
weeks because of adverse effects). Gefitinib administration was
delayed if the patient’s leukocyte and platelet counts were lower
than 1500 and 5000ml
 1, respectively, and was withheld until these
counts had recovered. Gefitinib administration was also delayed if
grade 3 or greater nonhaematological toxicities without nausea,
vomiting or alopecia occurred and was withheld until recovery to
grade 2.
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assessments were performed weekly or biweekly, where possible;
CT examinations of the target lesion were performed every month,
and magnetic resonance imaging of the whole brain and a bone
scan were performed every 3 months. The objective responses of
the patients were evaluated every month using the Response
Evaluation Criteria in Solid Tumours (RECIST) guidelines
(Therasse et al, 2000). Tumour response was centrally evaluated
by independent reviewers at an extramural conference and was
performed for the intent-to-treat population. All adverse effects
that occurred during gefitinib treatment were reported, and the
severity of the effects was graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 3.0.
Statistical analyses
The primary end point of this study was the response rate. A one-
stage design using the binominal probability was used to
determine the sample size. Assuming that a response rate of 50%
would indicate potential usefulness, whereas a rate of 25% would
be the lower limit of interest, and with a¼0.10 (two side) and
b¼0.20, the estimated accrual number was 23 patients. Estimating
that the EGFR-positive rate would be about 20%, the screening
number required to accrue 23 EGFR-positive patients was 115.
After assuming an inevaluability rate of o10%, the final required
screening number was 125.
The secondary end points of this study were toxicity, OS, PFS,
1-year survival (1Y-S) and the disease control rate (DCR). Survival
analyses were conducted on the intent-to-treat population using
follow-up data available as of 30 April 2007. The survival curves
were estimated using Kaplan–Meier plots.
RESULTS
Patient characteristics
Between March 2005 and January 2006, 118 patients were
prospectively screened from 15 institutions; 117 of them under-
went EGFR mutation analysis (tumour tissue was not available for
one patient). The median time required for the EGFR mutation
analysis was 12 days (range: 7–28 days). Among the 117 patients,
EGFR mutations were detected in 32 patients (27%), 14 of whom
had a deletion in or near E746-A750 (including one del E746-T751
ins A, two del L747-T751 and one del L747-T753 ins S) in exon 19.
A further 17 had L858R, and one had a L861Q point mutation in
exon 21 (Table 1).
Tissue samples from 17 patients (53%) were obtained by
transbronchial biopsy. The EGFR detection rates for the surgical
specimens and the bronchoscopic biopsy specimens were similar
(30 vs 25%). The EGFR mutations were significantly more frequent
in women (Pp0.02), in patients with adenocarcinoma (P¼0.001)
and in people who had never smoked (Po0.001) (Table 2). Finally,
28 patients (14 with deletions in exons 19 and 14 with point
mutations in exon 21) were actually registered and received
treatment with gefitinib, whereas four patients were dropped from
the study as they became ineligible because of tumour progression
during the time required for the mutation analysis.
Patient characteristics are listed in Table 3. In the initial
screening, there were 56 female patients (48%), 97 patients (83%)
with adenocarcinoma and 53 (45%) who had never smoked. The
frequency of these characteristics was higher among the patients
with EGFR mutations who were actually registered; namely, 18
patients (64%) were women, 27 (96%) had adenocarcinoma and 19
(68%) had never smoked. The median age of the 28 actually
registered patients was 68 years; 24 patients (86%) had a good
performance status (0–1), 22 (79%) had stage IV diseases and 17
(61%) were chemotherapy naive. Thoracic irradiation was contra-
indicated in one patient with stage IIIA disease because of the large
irradiation field that would have been required. All five patients
with stage IIIB diseases had malignant effusions. Four patients had
received adjuvant therapies; five had received platinum doublets or
a combination of gemcitabine and vinorelbine as their first-line
therapy. Two patients had received two regimens of platinum
doublets followed by docetaxel or pemetrexed. One patient had
received local radiation for pain control.
Response and survival
The objective tumour responses are listed in Table 4. The overall
response rate and DCR were 75% (95% CI: 57.6–91.0%) and 96%
(95% CI: 87.0–96.4%), respectively. Five out of ten male patients
(50%), six out of nine smokers (67%) and five out of eight male
smokers with adenocarcinoma (63%) achieved a PR. One female
nonsmoker with squamous cell carcinoma also achieved a PR.
Among the registered patients with EGFR mutations, the response
rate was no different between current/former smokers and those
who had never smoked (67 vs 79%) or between chemotherapy-
naive and postchemotherapy patients (77 vs 73%). Female and
patients with a mutational deletion in exon 19 tended to have a
higher response rate than male (89 vs 50%) and patients with a
missense mutation in exon 21 (86 vs 64%), respectively.
The median follow-up time was 18.6 months (range: 13.8–23.4
months). The median PFS time was 11.5 months (95% CI: 7.3
months to -) (Figure 1A). The median OS has not yet been reached,
and the 1Y-S was 79% (95% CI: 63.4–93.8%) (Figure 1B).
Table 1 Type of EGFR mutations (n¼32)
Characteristics No. of patients %
Exon 18 0 0
Exon 19 14 44
del E746-A750 10 32
del E746-T751 ins A 1 3
del L747-T751 2 6
del L747-T753 ins S 1 3
Exon 21 18 56
L858R 17 53
L861Q 1 3
EGFR¼epidermal growth factor receptor.
Table 2 Relationship between patient characteristics and EGFR mutation
status
EGFR mutation
positive (n¼32)
EGFR mutation
negative (n¼85)
Characteristics No. of Patients % No. of Patients % P
Sex
Male 11 34 50 59
Female 21 66 35 41 o0.02
Histology
Adenocarcinoma 31 97 66 78
Nonadenocarcinoma 1 3 19 22 ¼0.001
Smoking status
Never 21 66 31 36
Current/former 11 34 54 64 o0.001
EGFR¼epidermal growth factor receptor.
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Toxicity was evaluated in all eligible patients (Table 5). The most
frequent adverse events were rash, dry skin, diarrhoea, stomatitis
and elevated AST/ALT levels. Two patients experienced grade 3
rash and one patient experienced grade 3 keratitis; however, these
patients all achieved a PR, and the adverse effects subsided after
pausing gefitinib treatment for around 2 weeks. Four patients
experienced grade 3 hepatotoxicity; three of these patients had to
discontinue treatment for this reason.
One patient developed interstitial lung disease (ILD) (Ando et al,
2006). Ground-glass opacity was detected in the right upper lobe
19 days after the start of gefitinib administration, resulting in the
cessation of treatment. However, the lesion enlarged into bilateral
lung fields on day 25, and steroid therapy was initiated.
Nonetheless, the patient died of respiratory failure on day 48.
Two patients also experienced grade 1 ILD. They recovered
without steroid administration.
Subsequent treatment after disease progression
Of the 14 patients who become refractory to gefitinib and exhibited
disease progression, 10 received chemotherapy as their first
treatment regimen after gefitinib (Table 6); 5 patients received
platinum doublets and 1 patient received vinorelbine as a second-
line treatment; and 3 received docetaxel and 1 received platinum
doublet as a third-line treatment. In all, 4 out of the 10 patients
(40%) had a PR. Of the nine patients who become refractory to the
first treatment regimen after gefitinib, six received chemotherapy
as their second regimen after gefitinib, including one who received
gemcitabine, one who received docetaxel, and one who was re-
treated with gefitinib as a third-line therapy; two other patients
received docetaxel and one was re-treated with gefitinib as a
fourth-line therapy. Two of the six patients (33%) had a PR. The
two patients who received gefitinib re-treatment both had SD.
BAC features, EGFR amplification and T790M mutation in
exon 20
A total of 110 tissue samples were available for pathological review,
of which 90 were from adenocarcinoma; 33 of these specimens
(37%) revealed proportional BAC components in the specimen.
Among them, 15 were considered extensive and the remaining 18
were found to have minor BAC components. The 39 surgical
specimens included 36 from adenocarcinomas. The EGFR muta-
tions were detected in 12 out of the 36 adenocarcinoma specimens.
None of the samples with a BAC component, micropapillary
pattern or mucin production was associated with an EGFR
mutation (Table 7).
Data on EGFR gene copy numbers were available in only 12
samples. We used the criteria for defining a high EGFR gene copy
number (gene amplification or high polysomy, as determined
using FISH) that were described in a previous report (Cappuzzo
et al, 2005). A total of 7 out of the 12 samples had a high gene copy
number (FISH positive), and 6 (3 with EGFR mutations) out of the
7 samples had proportional BAC components. In all, 5 out of the 12
samples were FISH negative, only 1 (with no EGFR mutation) of
which had a BAC component. Two patients that were FISH
negative, BAC negative and EGFR mutation positive had SD when
treated with gefitinib.
Another EGFR mutation, T790M in exon 20, has been reported
to be associated with resistance to gefitinib (Kobayashi et al, 2005;
Pao et al, 2005). We checked for this mutation in six patients who
did not respond to gefitinib; however, the mutation could not be
identified in any of the patients.
DISCUSSION
We performed a multicentre phase II study examining the use of
gefitinib for advanced NSCLC in patients with EGFR mutations,
prospectively recruiting patients at the time of genetic screening
and avoiding a selection bias. All patients were registered in a
central database. All tissues were delivered from the local
participants to the central facility, where they were reviewed by a
pathology specialist and the EGFR mutation status was evaluated.
The median time for the EGFR mutation detection analysis was 12
days, which is probably an acceptable time lag before the start of
treatment for advanced NSCLC. However, a shorter period would
clearly be desirable for routine clinical practice. Indeed, 4 out of
the 32 EGFR-positive patients were dropped from the study
because of disease progression before their actual registration
Table 3 Patient characteristics of all registered patients (n¼28)
Characteristics No. of patients (%)
Age
Median 68
Range 49–89
Performance status
0 11 (39)
1 13 (47)
2 4 (14)
Sex
Male 10 (36)
Female 18 (64)
Histology
Adenocarcinoma 27 (96)
Squamous cell carcinoma 1 (4)
Large cell carcinoma 0 (0)
Adenosquamous carcinoma 0 (0)
Other 0 (0)
Smoking status
Never 19 (68)
Current/former 9 (32)
Stage
IIIA
a 1 (3)
IIIB 5 (18)
IV 22 (79)
Prior cancer therapy
Chemotherapy
No 17 (61)
One regimen (adjuvant) 4 (14)
One regimen (not adjuvant) 5 (18)
Two regimens 2 (7)
Recurrence after surgery 11 (39)
Radiation 1 (4)
aUnresectable, no indication for thoracic radiation because of a large radiation field.
Table 4 Response rate (n¼28)
Response No. of patients Response rate (%) 95% CI
Complete response 1 3.6
Partial response 20 71.4
Stable disease 6 21.4
Progressive disease 0 0.0
Not evaluable
a 1 3.6
Overall response 21 75.0 57.6–91.0
Disease control rate 27 96.4 87.0–96.4
CI¼confidence interval.
aOne patient was not evaluable because of a poor
evaluation of efficacy.
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detect EGFR mutations, and we have decided to use this assay in a
phase III trial. The EGFR mutation rates in transbronchial biopsy
samples were found to be the same as those in surgical specimens,
suggesting that this assay can also accommodate stage IV NSCLC.
We detected the two characteristic types of EGFR mutations (in
exons 19 and 21) in 44 and 56% of the patients, respectively
(Table 1); these percentages are identical to those in previous
reports from Japan (Shigematsu et al, 2005; Asahina et al, 2006;
Inoue et al, 2006; Yatabe et al, 2006; Yoshida et al, 2007). In
summary, we confirmed the feasibility of using the EGFR detection
assay in daily practice.
The overall response rate was 75%, which was comparable to
those of other phase II studies of gefitinib in patients with EGFR
mutations (Asahina et al, 2006; Inoue et al, 2006), despite our
study permitting the entry of patients who had previously received
up to two chemotherapy regimens. The DCR of 96% was relatively
high, and the median PFS of 11.5 months and 1Y-S of 79% were
also very promising. In a Korean study, Lee et al (2006) also
reported a very promising response rate (56%) and 1Y-S (76%) for
gefitinib in a prospective study of selected NSCLC patients with
adenocarcinoma and never/light smokers, defined as having
smoked no more than 100 cigarettes during one’s lifetime. In the
screening process for the present study, EGFR mutations were
significantly more frequent in women, patients with adenocarci-
noma and those who had never smoked. However, among the
patients who were selected according to their EGFR mutation
status, no differences in response were observed between never
smokers and current/former smokers or between chemotherapy-
naive and postchemotherapy patients. In a retrospective study,
Han et al (2006) directly compared clinical predictors (smoking
history, gender and histology) and the EGFR mutation status for
their ability to predict response and survival. They showed that
female never smokers with adenocarcinoma (three clinical
predictors) had a 33% response rate, whereas patients with a
positive EGFR mutation status had a 62% response rate.
Furthermore, in a multivariate analysis, only a positive EGFR
mutation status was associated with an improved OS, suggesting
that the EGFR mutation status should be analysed whenever
possible to optimise response predictions based on clinical
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Figure 1 (A) Progression-free survival (PFS) and (B) overall survival (OS) of all eligible patients (n¼28). The median PFS was 11.5 months. The median
OS has not yet been reached. The 1-year survival rate was 79%.
Table 5 Common adverse events (n¼28)
No. of patients (%)
Adverse events Grade 1 Grade 2 Grade 3 Grade 4
Haematologic
Anaemia 12 (43) 3 (11) 0 (0) 0 (0)
Leucopaenia 4 (14) 1 (4) 2 (7) 0 (0)
Neutropaenia 4 (14) 1 (4) 1 (4) 0 (0)
Thrombocytopaenia 3 (11) 0 (0) 0 (0) 0 (0)
Nonhaematologic
Rash 10 (36) 11 (39) 2 (7) 0 (0)
Dry skin 9 (32) 10 (36) 0 (0) 0 (0)
Nail changes 5 (18) 2 (7) 0 (0) 0 (0)
Keratitis 0 (0) 0 (0) 1 (4) 0 (0)
Fever 0 (0) 1 (4) 0 (0) 0 (0)
Fatigue 3 (10) 3 (10) 3 (10) 0 (0)
Diarrhoea 7 (25) 1 (4) 0 (0) 0 (0)
Constipation 1 (4) 0 (0) 0 (0) 0 (0)
Stomatitis 8 (29) 1 (4) 0 (0) 0 (0)
Gastritis 1 (4) 0 (0) 0 (0) 0 (0)
Anorexia 2 (7) 1 (4) 0 (0) 0 (0)
Nausea 3 (11) 1 (4) 0 (0) 0 (0)
Vomiting 2 (7) 2 (7) 1 (4) 0 (0)
Dyspnoea 2 (7) 0 (0) 1 (4) 0 (0)
ILD 2 (7) 0 (0) 0 (0) 1 (4)
a
Vertigo 1 (4) 1 (4) 0 (0) 0 (0)
Dysgeusia 0 (1) 1 (4) 0 (0) 0 (0)
Elevated AST/ALT 10 (36) 2 (7) 4 (14) 1 (4)
a
Elevated creatinine 2 (7) 1 (4) 2 (7) 0 (0)
ALT¼alanine transaminase; AST¼aspartate transaminase; ILD¼interstitial lung
disease.
aSame patient.
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detected in 16 out of 40 (40%) female never smokers with
adenocarcinoma who underwent the screening process, and 14 out
of these 16 patients (88%) achieved a response after undergoing
gefitinib therapy. We could not compare the predictive powers of
clinical predictors and the EGFR mutation status with regard to the
clinical benefits of gefitinib in this study. Thus, the need for EGFR
mutation testing among clinically favourable patients remains
uncertain. Decisions regarding the first-line therapy of choice for
patients with EGFR mutations or a clinically favourable profile
(nonsmoker with adenocarcinoma) must also await the results of
an ongoing randomised phase III study in an Asian population
(IPASS: Iressa Pan-Asian Study) comparing platinum doublets
with gefitinib.
In contrast, 50% of the men, 67% of the smokers and 63% of the
men who were smokers achieved a PR in this study. Furthermore,
one female nonsmoker with squamous cell carcinoma also
responded to gefitinib. The histological type of this tumour was
reassigned by a pulmonary pathologist, and the tumour was finally
confirmed to be a squamous cell carcinoma. Squamous cell
carcinoma harbouring an EGFR mutation is rarely seen but has
been previously reported (Asahina et al, 2006). In a Japanese phase
II trial of gefitinib for unselected chemotherapy-naive patients
(Niho et al, 2006), the response rates among smokers, men, and
patients with nonadenocarcinoma were 19, 13 and 10%, respec-
tively. Thus, NSCLC patients who are either smokers, men or have
a nonadenocarcinoma histology are unlikely to receive gefitinib
treatment as a first-line treatment instead of standard chemothera-
pies (platinum doublets), which yield a response rate of about 30%
(Schiller et al, 2002). Therefore, EGFR mutation screening may
have a higher impact on the selection of responders to gefitinib
treatment among these kinds of Asian patient subset (for example,
smokers with adenocarcinoma, and nonsmoking men or women
with nonadenocarcinoma).
The benefit of chemotherapy in general among patients with
EGFR mutations, compared with EGFR mutation-negative patients,
remains uncertain. Previous studies (Bell et al, 2005) have
suggested that patients with EGFR mutations tend to be more
sensitive to chemotherapy than those with wild-type EGFR. In the
present study, 40 and 33% of the patients responded to first- and
second-line chemotherapy regimens after gefitinib, respectively.
These relatively high response rates for refractory NSCLC suggest
that patients with an EGFR mutation-positive status are generally
sensitive to chemotherapy. Large-scale multivariate analyses, using
pooled data from prospective phase II or III trials in which the
EGFR mutation status was clearly confirmed, are needed to clarify
this point.
The toxicities observed in the present study were mostly
tolerable. Most of the common adverse events, like rash, diarrhoea
or hepatotoxicity, were mild and subsided after gefitinib admin-
istration was paused for a short period. One male smoker with
adenocarcinoma died of ILD. Thus, even among patients who are
selected based on their EGFR mutation status, men or smokers
may still be at risk for developing ILD; therefore, biomarkers to
predict ILD are needed.
Patients with exon 19 mutations tended to have a higher response
rate than those with a missense mutation in exon 21, consistent with
the findings of previous reports (Jackman et al, 2006; Riely et al,
2006). The Spanish Lung Cancer Group also reported on a
prospective phase II study of erlotinib in advanced NSCLC patients
with EGFR mutations (Paz-Ares et al, 2006). The overall response
rate was 82%. They also showed a difference in response rates
between patients with mutations in exons 19 and 21 (95 and 67%,
respectively). Exon 11 c-kit mutations are more closely correlated
with a good prognosis in patients with gastrointestinal stromal
tumour, who may benefit from lower doses of imatinib, whereas
patients with exon 9 mutations may require higher doses (Debiec-
Rychter et al, 2006). In the case of EGFR, functional differences
between mutation types may also exist.
We found no discernible associations between the EGFR
mutation frequency and the presence of a BAC component.
Several reports, including that of Hirsch et al (2005) suggest that a
higher EGFR copy number is correlated with BAC histological
features. We also found an association between a high EGFR copy
number and the presence of a BAC component, even though the
number of specimens examined was relatively small. In a study on
erlotinib, the presence of a BAC component was clearly associated
with EGFR amplification. As the EGFR mutation rate is lower in
western populations than in Asian populations, the EGFR gene
copy number might be a more useful biomarker in western
populations, especially with regard to the use of erlotinib.
Table 6 Subsequent treatments after failure to respond to gefitinib (n¼28)
Gefitinib treatment No. of Patients
1st regimen
after gefitinib No. of patients
2nd regimen
after gefitinib No. of patients
1st line 17 Plt doublet 5 Gem or Doce 2
Gefitinib
a 1
VNR 1 — -
2nd line
b 4 Doce 2 Doce 1
Plt doublet 1 Doce 1
2nd line 5 Doce 1 Gefitinib
a 1
3rd line 2 — — — —
Total 28 10
Response 4/10 2/6
Doce¼docetaxel; Gem¼gemcitabine; Plt¼platinum; VNR¼vinorelbine.
aBoth patients had an SD response after gefitinib re-treatment.
bFirst regimen as systemic
chemotherapy after adjuvant treatment.
Table 7 Bronchial alveolar carcinoma (BAC) features and EGFR
mutation status
EGFR mutation
+   P-value
Surgically resected adenocarcinoma case 12 24
BAC component
Yes 8 17 1.0
No 4 7
Micropapillary pattern
Yes 4 12 0.48
No 8 12
Mucin production
Yes 1 5 1.0
No 11 19
EGFR¼epidermal growth factor receptor.
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sIn conclusion, gefitinib treatment for patients with advanced
NSCLC harbouring an EGFR mutation demonstrated a promising
activity in patients with a good performance status. Patient
screening according to EGFR mutation status may be a useful
tool in daily practice and will likely have a great impact on the
selection of patients who are likely to benefit from gefitinib
treatment.
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